MannKind | MNKD - Gross Profit On Sales


MannKind reported $68.33M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Adma Biologics USD 88.82M 13.19M Dec/2025
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Insmed USD 256.46M 38.78M Mar/2026
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
MacroGenics USD 31.11M 30.14M Dec/2025
MannKind USD 68.33M 9.98M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Novavax USD 125.04M 76.09M Dec/2025
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Pfizer USD 11.04B 1.24B Mar/2026
Sanofi EUR 8.45B 1.31B Dec/2025
Xencor USD 21M 22.61M Sep/2025